China Diagnostic Reagent Industry (biochemical, molecular & immunodiagnostic) 2016 Forecasts in New Research Report at ChinaMarketResearchReports.com
Dallas, TX (PRWEB) July 30, 2014 -- With the accelerated aging of the Chinese population, the increase of personal health expenditure as well as the improved medical care facilities and government health care system, China diagnostic reagent industry has been developing quickly, especially in vitro diagnostic reagents occupy over 90%. In 2013, Chinese in vitro diagnostics market size reached RMB22.98 billion, of which RMB16.61 billion came from in vitro diagnostic reagents.
Chinese in vitro diagnostic reagent market consists of biochemical diagnostic reagents, immunodiagnostic reagents and molecular diagnostic reagents. Among them, the immune reagents and biochemical reagents account for a relatively higher combined proportion, such as around 65% in 2013.
Currently, about 40%-50% share of the Chinese in vitro diagnostics market has been dominated by foreign companies represented by Roche, Siemens, Abbott and Johnson & Johnson. Although there are 300-400 local enterprises in China in vitro diagnostics industry, the top ten Chinese companies which rank by production scale only seize 30% market share, reflecting a low industry concentration degree.
Purchase a copy of this report @ http://www.chinamarketresearchreports.com/contacts/purchase.php?name=114875 .
Mindray Medical, KHB, Fosun Pharmaceutical, Maker Biotechnology and Da An Gene act as giants in China in vitro diagnostics industry. Especially, Mindray Medical and KHB achieved the respective in vitro diagnostics revenue of RMB2.0458 billion and RMB1.0572 billion in 2013, accounting for 13.5% of the total jointly.
In 2014, a number of local Chinese diagnostic reagent companies (including BSBE, Maker Biotechnology, Health BioMed, Wondfo, Thalys) intend to step in the capital market through IPO because they are optimistic about the prospects of the diagnostic reagent industry; the raised funds will be used in the expansion of the existing projects or the construction of new projects. SHINVA, Humanwell Healthcare and Zhongyuan Union Stem Cell Bioengineering have entered the diagnostic reagent industry through acquisitions.
The report covers the following:
Status quo of China diagnostic reagent industry, including overview, market structure, import, export, competition pattern and so on.
Development environments and trends of China diagnostic reagent industry, embracing macroeconomy, medical situation, and relevant policies.
Operation and diagnostic reagent business of 17 major companies in China diagnostic reagent industry.
Complete report is available at http://www.chinamarketresearchreports.com/114875.html.
Few Points from Table of Contents
4 Major Enterprises
4.1 Shanghai Kehua Bio-engineering Co., Ltd. (KHB)
4.2 Beijing Strong Biotechnologies, Inc (BSBE)
4.3 Da An Gene
4.4 Fosun Pharmaceutical
4.5 Beijing Leadman Biochemistry Co., Ltd.
4.6 Livzon Pharmaceutical Group Inc.
4.7 Mindray Medical
4.8 Biosino Bio-Technology & Science Inc.
4.9 Maker Biotechnology
4.10 Sinocare
4.11 Beijing Kinghawk Pharmaceutical Co., Ltd.
4.12 Bohui Innovation
4.13 Health BioMed
4.14 Wondfo
4.15 Thalys
4.16 SHINVA
4.17 Humanwell Healthcare
List of Charts
Classification of In Vitro Diagnostic Reagents (by Detection Principle)
In Vitro Diagnostic Reagent Categories and Products (by National Policies)
Diagnostic Reagent Industry Chain
China’s In Vitro Diagnostics Market Size, 2009-2013
China’s In Vitro Diagnostic Reagent Market Structure, 2013
China’s Diagnostic Reagent Import Volume, 2008-2013
China’s Diagnostic Reagent Import Value, 2008-2013
China’s Diagnostic Reagent Import Sources and Value, 2012-2013
China’s Diagnostic Reagent Export Volume, 2008-2013
China’s Diagnostic Reagent Export Value, 2008-2013
Top 10 Destinations of Chinese Diagnostic Reagents by Export Volume and Value, 2012-2013
Diagnostic Instrument Comparison between Domestic and Foreign Enterprises
Competition Pattern of China Diagnostic Reagent Industry
In Vitro Diagnostics Revenue and Market Share of Major Diagnostic Reagent Companies in China, 2013
China’s GDP and YoY Growth Rate, 2004-2013
China’s Total Population and YoY Growth Rate, 2006-2013
Population of 65-year-old People (or Older) and % of Total Population in China, 2004-2013
China's Health Expenditure and % of GDP, 1980-2013
China's Per Capita Health Expenditure and YoY Growth Rate, 2006-2012
Number of Medical Institutions In China, 2012-2013
Workload of Health Institutions in China, 2012-2013
Main Policies of China Diagnostic Reagent Industry, 2010-2013
Development Process of Roche Diagnostics
Integrated Development Strategies of Global Leading Diagnostic Reagent Companies
KHB’s Revenue and Net Income, 2009-2013
KHB’s Revenue (by Product), 2009-2013
KHB’s Revenue Structure (by Product), 2009-2013
KHB’s Revenue (by Region), 2009-2013
KHB’s Revenue Structure (by Region), 2009-2013
KHB’s Gross Margin, 2009-2013
KHB’s Gross Margin (by Product), 2009-2013
KHB’s Gross Margin (by Region), 2010-2013
KHB’s R & D Costs and % of Total Revenue, 2011-2013
Key National Projects Involved with KHB
KHB’s Revenue from Top 5 Clients and % of Total Revenue, 2008-2013
Comparison between KHB’s Top 5 Clinets, 2012-2013
Comparison between KHB’s Top 5 Suppliers, 2012-2013
KHB’s Medical Instrument Categories and Products, 2013
KHB’s Revenue and Net Income, 2012-2016E
BSBE’s Revenue and Net Income, 2011-2013
BSBE’s Revenue and Structure (by Product), 2011-2013
BSBE’s Gross Margin, 2011-2013
Browse more reports on Life Sciences Industry @ http://www.chinamarketresearchreports.com/cat/life-sciences.html.
About Us:
ChinaMarketResearchReports.com (http://www.chinamarketresearchreports.com/ .) is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.
Ritesh Tiwari, Chinamarketresearchreports.com, http://www.chinamarketresearchreports.com/, +1 (888) 391-5441, [email protected]
Share this article